Eisai Prepares For Belviq Launch: An Interview With CEO Lonnel Coats
This article was originally published in The Pink Sheet Daily
Eisai Inc.’s President and CEO Lonnel Coats discussed his approach to the U.S. obesity market and how he plans to position Belviq. The company needs to replace lost revenue from its off-patent blockbuster Aricept but Coats thinks he has the right mix of label, product and experience to win.
You may also be interested in...
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.
Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.